Colorectal Neoplasms Clinical Trial
— GLUTOXOfficial title:
A Multicentre, Randomized, Open-label, Phase III Study Comparing the Efficacy of Oral Glutamine and Calcium-magnesium With Calcium-magnesium Alone in the Prevention of Oxaliplatin-induced Neurotoxicity in Patients With Colorectal Cancer Treated With Oxaliplatin in Adjuvant or 1st Line Metastatic Settings.
Verified date | June 2013 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
Primary Objective:
To assess the benefit of glutamine when added to calcium-magnesium on the occurrence of
grade 2, 3 and 4 peripheral sensory neuropathy (PSN) related to oxaliplatin with the
National Cancer Institute-Common Terminology Criteria for Adverse Event (NCI-CTCAE) scale
taking into account the time from start of oxaliplatin at which the first event occurred.
Secondary Objective:
To determine cumulative dose of oxaliplatin and time when the first occurrence of grade 2, 3
or 4 PSN.
To determine the incidence of dose-reductions, dose-delays and discontinuations of
oxaliplatin due to PSN grade 3 or 4.
To assess effects of glutamine when added to calcium-magnesium on patients-reported outcomes
using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity
12 items questionnaire (FACT/GOG NTX-12) subscale.
To evaluate the incidence of diarrhea. To determine Progression Free Survival (PFS) in
metastatic patients.
Status | Completed |
Enrollment | 200 |
Est. completion date | March 2013 |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: 1. Histologically- or cytologically- proven adenocarcinoma of the colon or rectum. 2. Disease either in adjuvant or 1st line metastatic setting. 3. Eastern Cooperation Oncology Group (ECOG) performance status inferior or equal to 2. 4. At least 4 weeks following any major surgical procedure(s) and recovery from any surgical sequelae. 5. Electrocardiogram (ECG) with no acute or recent changes within limit of normal range, and not presenting abnormalities contraindicating the proposed chemotherapy. 6. Adequate liver and kidney function: - Total bilirubin inferior to 1.5 ULN - Serum creatinine inferior to 150 umol/L - Creatinine clearance (ClCr) superior to 45 mL/min - ALT/AST inferior to 3 ULN - Alkaline phosphatase inferior or equal to 2 ULN, unless liver metastases are present and documented at baseline by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scans (inferior or equal to 3,5 ULN in that case). 7. Adequate hematological function: - Neutrophils superior or equal to 1.5 x 109/L - Platelet count superior or equal to 100 x 109/L - Hemoglobin superior to 9 g/dL Exclusion criteria: 1. Any condition or past medical history that contra-indicates treatment with oxaliplatin, 5-fluorouracil (5-FU), leucovorin (LV) or capecitabine as reported in the approved labeling information. 2. Previous oxaliplatin-based chemotherapy. 3. Previous or current diagnosis of PSN. 4. Concomitant treatments with drugs/ingredients reported to have a potential activity in preventing PSN: carbamazepine, amitriptyline, gabapentin, phenytoin, glutathione, alpha-lipoic acid, celecoxib, amifostine, venlafaxine, vitamin B1 (thiamine), B6 (pyridoxine). 5. History of known allergy to oxaliplatin or other platinum agents, 5-FU, LV or capecitabine. 6. History of known allergy to glutamine or to calcium-magnesium. 7. Participation in another clinical trial with any investigational drug within 30 days prior to study screening. 8. Uncontrolled intercurrent illness: e.g. high blood pressure, unstable angina, symptomatic congestive heart failure (New York Heart Association Classification III or IV), 9. Serious cardiac arrhythmia, diabetes, or active infection. 10. Concurrent active cancer originating from a primary site other than colon or rectum. 11. Presence of any symptom suggesting brain metastasis. 12. Patients who are pregnant or breast-feeding 13. Patients (males and females) with reproductive potential not implementing accepted and effective method of contraception 14. For patient who will receive Bevacizumab: Bevacizumab is contraindicated in patients with known hypersensitivity to any components of the product to Chinese hamster ovary cell product or other recombinant human or humanized antibodies The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Investigational Site Number 0001 | Greenfield Park | |
Canada | Investigational Site Number 124-005 | Laval | |
Canada | Investigational Site Number 124-007 | London | |
Canada | Investigational Site Number 124-014 | Moncton | |
Canada | Investigational Site Number 124-004 | Montreal | |
Canada | Investigational Site Number 124-006 | Montreal | |
Canada | Investigational Site Number 124-011 | Montreal | |
Canada | Investigational Site Number 124010 | Montreal | |
Canada | Investigational Site Number 124-015 | Oshawa | |
Canada | Investigational Site Number 124-012 | Ottawa | |
Canada | Investigational Site Number 124-003 | Quebec | |
Canada | Investigational Site Number 124-017 | Rimouski | |
Canada | Investigational Site Number 124-002 | Toronto | |
Canada | Investigational Site Number 124-016 | Winnipeg |
Lead Sponsor | Collaborator |
---|---|
Sanofi |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurence of peripheral sensory neuropathy (PSN) grade 2, 3 and 4 assessed by the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE) | Every cycle i.e. 2 or 3 weeks according to the treatment arm | No | |
Secondary | Cumulative dose of oxaliplatin and time of onset when the first PSN grade 2, 3 or 4 occurs | Every cycle i.e. 2 or 3 weeks according to the treatment arm | No | |
Secondary | Dose-reduction, dose-delay and discontinuation of oxaliplatin due to PSN grade 3 or 4 | Every cycle i.e. 2 or 3 weeks according to the treatment arm | No | |
Secondary | Patient self-reported neurotoxicity scale for chronic peripheral neuropathy | Every cycle i.e. 2 or 3 weeks according to the treatment arm | No | |
Secondary | Progression Free Survival / PFS (for metastatic patients) | Every cycle i.e. 2 or 3 weeks according to the treatment arm | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04552093 -
Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)
|
Phase 2/Phase 3 | |
Completed |
NCT04192565 -
A Prospective Investigation of the ColubrisMX ELS System
|
N/A | |
Completed |
NCT05178745 -
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
|
||
Recruiting |
NCT03561350 -
Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
|
||
Recruiting |
NCT06128798 -
Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery.
|
N/A | |
Recruiting |
NCT03602677 -
Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage
|
N/A | |
Completed |
NCT03631407 -
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
|
Phase 2 | |
Withdrawn |
NCT04192929 -
Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy
|
N/A | |
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Completed |
NCT02889679 -
Underwater Resection of Non-pedunculated Colorectal Lesions
|
N/A | |
Terminated |
NCT02842580 -
De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02564835 -
Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer
|
N/A | |
Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT02149108 -
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
|
Phase 3 | |
Completed |
NCT02599103 -
The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects
|
N/A | |
Completed |
NCT01719926 -
Phase I Platinum Based Chemotherapy Plus Indomethacin
|
Phase 1 | |
Completed |
NCT01669109 -
Hatha Yoga for Patients With Colorectal Cancer
|
N/A | |
Recruiting |
NCT01428752 -
Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer
|
N/A | |
Completed |
NCT01978717 -
General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer
|
N/A | |
Completed |
NCT01877018 -
Colorectal Cancer Screening in Primary Care
|
N/A |